EUCTR2009-016629-33-DE进行中（未招募）不适用
A 12 day placebo- and reference-controlled, double-blind, single center, randomized, phase II clinical study with an intraindividual comparison, investigating the anti-psoriatic efficacy and the tolerability of LAS41002 lotion in a psoriasis plaque test - Efficacy and tolerability of LAS41002 lotion in a psoriasis plaque test
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •18 to 75 years of age
- •Caucasian men and women (skin type I to IV, Fitzpatrick 1974)
- •Mild to moderate chronic plaque psoriasis
- •At least one stable psoriatic plaque (stable plaque = plaque with no major changes in the size and no new plaque formation within the last two weeks prior screening. Changes in scaling and minor changes in erythema are allowed) in an area sufficient for product application
- •All patients must give written informed consent before any assessment is performed.
- •Psoriasis must be amenable for local therapy
- •Willingness to actively participate in the study and come to scheduled visits
- •Willingness to discontinue the use of cosmetic products (e.g. soaps, creams, moisturizers) in the treatment area throughout the course of the study
- •negative urine pregnancy test (in female patients of child bearing potential)
- •Reliable methods of contraception which result in a low failure rate (i.e. less than 1% per year) for women of childbearing potential (implants, injectables, combined oral contraceptives, some intrauterine-devices, sexual abstinence or vasectomized partner)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who need systemic treatment for their body psoriasis
- •Severe forms of psoriasis and the following forms of psoriasis
- •erythrodermatica
- •exfoliative
- •arthropathica
- •Widespread chronic stationary psoriasis
- •Changes in the expression of psoriasis within the last 6 weeks prior screening
- •Intensive UV-light exposure within two weeks before the beginning of the test as well as during the study and four weeks after the end of the study at the test area
- •Topical treatment of the test area (see table below):
- •Corticosteroids, antibiotics4 weeks prior to study day 1 and during conduct of study
- •Retinoids6 weeks prior to study day 1 and during conduct of study
- •Anti-inflammatory substances2 weeks prior to study day 1 and during conduct of study
- •Vitamin A analogs,
- •Vitamin D analogs,
- •Immunosuppressants,
- •Anthracen derivates2 weeks prior to study day 1 and during conduct of study
- •Salicylic acid preparations During conduct of study
- •Tar2 weeks prior to study day 1 and during conduct of study
- •UVB therapy2 weeks prior to study day 1 and during conduct of study
- •PUVA therapy4 weeks prior to study day 1 and during conduct of study
- •Neutral emollients1 week prior to study day 1 and during conduct of study
- •Topical treatment of all other body regions with corticosteroids or immunosuppressants in case more than 20 % of the body surface area is treated
- •Treatment with any non-marketed drug substance (i.e. an agent which had not yet been made available for clinical use following registration) within 4 weeks prior to study day 1
- •Systemic treatment that may interfere with the investigational product (see table below):
- •Corticosteroids, antibiotics4 weeks prior to study day 1 and during conduct of study
- •Retinoids6 weeks prior to study day 1 and during conduct of study
- •Vitamin D supplements, hydroxycarbamide, azathioprine, meth-otrexate, cyclosporine4 weeks prior to study day 1 and during conduct of study
- •Immunomodulators3 months prior to study day 1 and during conduct of study
- •Treatment with biologicals with a possible effect on psoriasis6 months prior study day 1 and during conduct of study
- •Antiphlogistics
- •(minor pain relief medicine like acetyl salicylic acid or acetaminophene if not more than 1000 mg per day is allowed)4 weeks prior to study day 1 and during conduct of study
- •Planned initiation of, or changes to concomitant medication that could affect psoriasis (e.g. beta blockers, anti-malaria drugs, lithium)8 weeks prior to study day 1 and during conduct of study
- •Specific skin diseases (such as tuberculosis or syphilis)
- •Skin infections caused by bacteria or viruses or fungal skin infection
- •Varicella zoster
- •Skin reactions after immunization
- •Rosaceae, perioral dermatitis in test area
- •Moderate or severe illness within the last two weeks before first exposure
- •Known infectious diseases (e.g. hepatitis or AIDS)
- •Other inflammatory skin diseases that may confound the evaluation of psoriasis
- •Known hypersensitivity to any of the study drugs, to ingredients of the study drugs, to drugs of similar chemical classes or to plaster
- •History of malignancy of any organ system
- •Pregnancy or lactation
- •Psychiatric conditions that might limit the participation in the trial and/or that lead to the assumption that the ability to completely understand the consequences of consent is missing
- •Any history of drug addiction or alcoholism in the past 3 years
- •Patients with poor compliance
- •Patients, who are i
研究者
相似试验
进行中（未招募）
不适用
A 13 day placebo- and reference-controlled, double-blind, monocentric, randomized, intraindividual comparative clinical phase IIa study, investigating the efficacy and tolerability of valrubicin cream 0.01 %, 0.1 % and 1 % in a panel of 24 patients with Psoriasis in a Psoriasis plaque testMild to Moderate Plaque PsoriasisMedDRA version: 9.1Level: LLTClassification code 10037153Term: PsoriasisEUCTR2007-005035-29-DEValderm ApS
招募中
不适用
A 12-week randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of HX112 on menopausal symptoms.Diseases of the genitourinary systemKCT0007932Helixmith120
已完成
Unknown
Black camin extract powder health functional food human study of evaluate for body fat reductioEndocrine, nutritional and metabolic diseasesKCT0008445ARI BnC88
已完成
2 期
A clinical evaluation of a novel olive leaf formulation for heart health.ACTRN12613000841774The University of Newcastle40
进行中（未招募）
不适用
The effect of tocilizumab in children who have arthritis which can include fever, rash, inflammation of the lungs or heart, or enlarged spleen, liver or lymph nodes.EUCTR2007-000872-18-CZF. Hoffmann-La Roche Ltd.108